Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1734)	11/5/2007 11:27:59 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ENMD's spike on Oct 25 was apparently due to its presentation in Frisco of the results of its cell cycle inhibitor, MKC-1, in preclinical RCC models. Today's spike is apparently related to the presentation tomorrow by J.B., its CEO at the R&R Healthcare Conference in N.Y. <g> The stock has been up today 24% & is still up 21%, trading above its Oct25-Oct26 double top at the $1.60 level bigcharts.marketwatch.com The stock still has a good amount of resistance at the $1.75 level bigcharts.marketwatch.com It needs to close above $2 in order to get off from the DT coming from its March 2005 H at $4.80, but it seems that the R/R isn't bad at present levels.<g> bigcharts.marketwatch.com Bernard